


# A candidate gene study of the type I interferon pathway implicates *IKBKE* and *IL8* as risk loci for SLE

Johanna K. Sandling, Sophie Garnier, Snaevar Sigurdsson, Chuan Wang, Gunnel Nordmark, Iva Gunnarsson, Elisabet Svenungsson, Leonid Padyukov, Gunnar Sturfelt, Andreas Jönsen, Anders A. Bengtsson, Lennart Truedsson, Catharina Eriksson, Solbritt Rantapää-Dahlqvist, Anders Mälarstig, Rona J. Strawbridge, Anders Hamsten, Lindsey A. Criswell, Robert R. Graham, Timothy W. Behrens, Maija-Leena Eloranta, Gunnar Alm, Lars Rönnblom and Ann-Christine Syvänen

## Supplementary information



**Figure S1** Q-Q plot of association results in the discovery phase. The observed P-values are plotted against the theoretical distribution, the deviation from the null distribution suggests the presence of multiple weak associations in the data. Only nine associated SNPs would be expected by chance with P values < 0.01, and after removal of the SNPs in the 14 genes included based on prior evidence for association to SLE, we observed 20 ( $P = 0.030$ , Fisher's exact test), which indicates the presence of true associations in our data.

**Table S1** Number of SLE patients and controls analysed

	<i>Discovery</i>		<i>Confirmation</i>		<i>Replication</i>		<i>Total</i>	
	SLE	Ctrl	SLE	Ctrl	SLE	Ctrl	SLE	Ctrl
<i>Sweden</i>								
Uppsala	131	161	19	291	-	-	150	452
Stockholm	203	187	114	161	-	-	317	348
Lund	156	195	-	-	-	-	156	195
Umeå	-	-	260	520	-	-	260	520
(Broadbent <i>et al.</i> 2008)	-	-	-	673	-	-	0	673
<i>US</i>								
(Hom <i>et al.</i> 2008)	-	-	-	-	1 435	3 583	1 435	3 583
(Gateva <i>et al.</i> 2009)	-	-	-	-	-	4 564	0	4 564
<i>Sum</i>								
Pre-QC							2 318	10 335
Post-QC							2 136	9 694

**Table S2** Sequences of primers used in the confirmatory phase. Sequences are given in the 5' to 3' direction. SNPs were genotyped in either 12 or 48-plex assays using the SNPstream system.

**A** PCR primers

<i>SNP</i>	<i>PCR forward primer</i>	<i>PCR reverse primer</i>
rs1539243	ARGTGAGGGAGTTTGAGGTC	CAAGCACCGGACCTACCG
rs17433930	TACTGGCATCCTCAGAGCT	TTCTTCCAGGAGCTCAGACT
rs3754974	TAGTTCCTCCTTATCTTAGTCTAATAGC	GAAAATTATTTACCAGAAGCAGAAGT
rs13397244	GAAGTCAACCAGATTCATTAATAGT	ATTTATTGAGACTTCTGAATATAAACCTAAG
rs12476789	ATGTCTTTGAGATCTATCTTGTCTCTC	CATCTCCCACTAAGTAGCAATGA
rs7600342	TTTCAATCCTTCAGGTAAGTATAAT	AATCCTGTGTTTCGGTCCT
rs3754972	AATAAACCAAGTTCTACTGGTTATTTTC	AAAAAAGTACAAAGATTTTGACCAC
rs1267075	AATCCTTGACTGAAATGTCTTTAAATA	GGCTCCAGGAATGACTTGATA
rs3769972	ATAATTTCTAGACAAGAGCCAGAATTAT	TAAATGAAATGGCTCATTCAA
rs10178063	TCCAATCTCCATTCAATCCTT	AGAGAGTGAAGGAAAGGAGCC
rs16833155	TGAAGGGCTTTAGGGTTGTAT	ATATTCAGCCATTTATTTTTGTTCTG
rs2030171	AGCAAAGAAAAGTCTTCTGCTC	TTTTCTAATCTGTGGGATGGG
rs10199181	ATTTAACCTAAAAATTCCTTCTGT	TTATTGGTATTTAGAGAAGTAATAGAGACTAACT
rs16833172	TTTTTCAGTTCAGTTTTATTTTACCTG	TGGGTTCGCTTGGCTAAT
rs17817900	ATCCTCAAATCTTAATTGATTCTTCC	AATGGATTTAAAGGTAGATAAGGGC
rs4694178	AATTTAGTTTAGTGATGGTCTGGTG	ATATGCCAGCAAAAATACCTCTC
rs734187	AATATTCTGGGCATTGACTTAGC	TTTTCAAATTGACTTGCTTTCC
rs2269103	TAAATCACTATCGGGTTCTG	TTGCATATGTAGTAATGGTATTTTCATT
rs1331314	ACACACTACATTCTGATAACAAAGA	ATAAGAGTTTCAAATTGCATTAGATGT
rs2073320	GTGAAATAGAACATTTATAAAGGCG	AATTACCTTTCATTTTCGTTTGT
rs5030482	AAATTAAGGCTGATCTAYAACGCT	GAGACCCGCACTAGTATAAGCT
rs5030472	TCCACCTCAAATCATCTACATTG	TGAAATAGTTTTCCAAGAAGACAAA
rs2303439	TTTAAACTGTATTGTCAATGGCTG	TTTCCTTCTCTATAACTTTTGAAAGTAG
rs6503691	AAAGAAGCAACAAGGAAAAATG	TGTTCTTCTATTGTAATATGCAGTG
rs2289863	TACTACCCCTCCAATAAGCCC	TGACAGTGATGCGGTTGG

**B** Minisequencing primers

<i>SNP</i>	<i>Extension primer containing tag-sequence</i>	<i>Strand</i>	<i>Alleles</i>	<i>Assay</i>
rs1539243	CGCAGAAGCAACTCACTTCTTGCGGAAGCTGAACCACCAGAACAT	Forward	C/T	48-plex
rs17433930	AACATCCACGCAACTCATAcAGTGGAAACAGGGAGATCTGGATTT	Forward	C/T	48-plex
rs3754974	CAGAACATCCTCAGAAGCAATCATGTATTTTCATCTCTTTTTGCAT	Forward	C/T	48-plex
rs13397244	AGCAAGACCACCTAGACCAGGCACATCAAAGATTTGACTGAGAAC	Forward	C/T	12-plex
rs12476789	CGACTGTAGGTGCGTAACTCTTAAGATGATTAGAGTATTGATAGG	Forward	A/G	12-plex
rs7600342	AGCGATCTGCGAGACCGTATTTTCATTACAGAGGAAGAAACAAA	Forward	A/G	12-plex
rs3754972	AGCGATCTGCGAGACCGTATAGTTTGATGTAATATTTCTTTTGG	Forward	A/T	12-plex
rs1267075	CAGCCATCCATTCACTATCTACTTCTGCGGTGCTTTAAGTGTCTT	Forward	C/T	48-plex
rs3769972	ATCTAACGCACCTACGACCTGGTCACTTGGGAGAGAATATTATGT	Forward	C/T	48-plex
rs10178063	GCAAGCCATCAGCTAATACAGACTTGGGCTGAATTTAAACTC	Forward	C/T	48-plex
rs16833155	GGCTATGATTCGCAATGCTTCTGTAGGTACCCAGATTTCTTGTG	Reverse	A/G	12-plex
rs2030171	GATCCATCAACAGACATCACCCCTTACTTGGACAACCTGCTCACTC	Reverse	C/T	48-plex
rs10199181	GGCTATGATTCGCAATGCTTATGCTATATTTACTGATGCTGTAGA	Forward	A/T	12-plex
rs16833172	AGTAGCCTAACAGCACTCGAAGGCGTTGCAGCTCCCATTGCCTGA	Reverse	C/T	48-plex
rs17817900	AATAAGCTCACCACCGTCAAGCAGAAGGAGGCAGCAGAAGAGATG	Reverse	C/T	48-plex
rs4694178	ACGCACGTCCACGGTGATTTTTTCTATTGGTTGTCCAAAGGAAG	Forward	A/C	12-plex
rs734187	AGACCGACAAGCAATCTACAGAGTCATGAATCTGGACTCCAAGTG	Reverse	C/T	48-plex
rs2269103	CAGCACTATTACCATCAGTACTGACAATAACTTAATTGGGCCT	Reverse	C/T	48-plex
rs1331314	GCGGTAGGTTCCCGACATATAATGGTGCTGGGGTTTCTATACACT	Forward	CG	12-plex
rs2073320	CCACTCAACTCCACGAATACACATCTGGCAGAGTACTGAGTCAC	Reverse	C/T	48-plex
rs5030482	CCATAACAACCTACCAGCCAAAGTTGTCTGGTAATGAGAGATGAC	Reverse	C/T	48-plex
rs5030472	CACTAGTCATAACGCAGCCTGATTTGAGGAACTACAAGTAGTTTGT	Reverse	C/T	48-plex
rs2303439	ACAACCTCACGCAAGTACCATTGATGGTTTATGTGCTGCACCTATTCA	Reverse	C/T	48-plex
rs6503691	CAGAATAGCCACGCCTAGATTTTGGCTGTGACATAAAGATTAATG	Reverse	C/T	48-plex
rs2289863	CACCGCTATCAACAGACTTGGGCCGTGCCGCCCATCAACCTCAC	Forward	C/T	48-plex

**Table S3** List of IFN related genes included in the discovery phase<sup>1</sup>**A** TLRs and intracellular sensors and their signaling pathways and transcription factors, with a focus on PDC and regulation of IFN-genes

<i>Gene</i>	<i>Location</i>	<i>SNP with lowest P</i>	<i>P<sub>Chi2</sub></i>	<i>Comment</i>
<i>AZI2</i>	chr3:p24.1	rs12054402	0.20	
<i>DDX58/RIG-I</i>	chr9:p21.1	rs4013911	0.026	
<i>DHX58/LGP2</i>	chr17:q21.2	rs2074159	0.11	
<i>FADD</i>	chr11:q13.3	rs10898853	0.17	
<i>IKBKe</i>	chr1:q32.1	rs1539243	0.0033	
<i>IRAK4</i>	chr12:q12	rs4251520	0.44	
<i>IRF1</i>	chr5:q23.3	rs12657912	0.29	
<i>IRF2</i>	chr4:q35.1	rs17075769	0.011	
<i>IRF3</i>	chr19:q13.33	rs2304207	0.29	
<i>IRF4</i>	chr6:p25.3	rs6899334	0.022	
<i>MyD88</i>	chr3:p22.3	rs4988457	0.33	
<i>RIPK2</i>	chr8:q21.3	rs390993	0.23	
<i>SPP1</i>	chr4:q22.1	rs1126616	0.29	
<i>TANK</i>	chr2:q24.2	rs3754974	0.0055	
<i>TBK1</i>	chr12:q14.2	rs7298692	0.45	
<i>TIRAP</i>	chr11:q24.2	rs1786704	0.183	
<i>TLR3</i>	chr4:q35.1	rs7657186	0.33	
<i>TLR4</i>	chr9:q33.1	rs5030717	0.19	
<i>TLR5</i>	chr1:q41	NA	NA	Failed assay design
<i>TLR7</i>	chrX:p22.2	rs1638596	0.067	
<i>TLR8</i>	chrX:p22.2	rs2109134	0.43	
<i>TLR9</i>	chr3:p21.2	rs352140	0.64	
<i>TRAF3</i>	chr14q:32.32	rs10137035	0.02	
<i>TRAF6</i>	chr11:p12	rs5030482	0.0029	
<i>TRAM1</i>	chr8:q13.3	rs28491596	0.12	
<i>TRIF/TICAM1</i>	chr19:p13.3	rs7255265	0.18	
<i>VISA</i>	chr20:p13	rs7262903	0.11	

**B** Functionally important membrane molecules on PDC

<i>Gene</i>	<i>Location</i>	<i>SNP with lowest P</i>	<i>P<sub>Chi2</sub></i>	<i>Comment</i>
<i>CLEC4C/CLECSF7</i>	chr12:p13.31	rs6488610	0.018	
<i>CXCR3</i>	chrX:q13.1	rs2280964	0.41	
<i>CXCR4</i>	chr2:q21.3	rs2228014	0.077	
<i>FCGR2A</i>	chr1:q23.3	rs1801274	0.18	
<i>FCGR2B</i>	chr1:q23.3	rs2333845	0.11	
<i>NRP1</i>	chr10:p11.22	rs1331314	0.0020	

**C Type I IFN and other cytokine genes regulated via TLR and RLR pathways**

<i>Gene</i>	<i>Location</i>	<i>SNP with lowest P</i>	<i>P<sub>Chi2</sub></i>	<i>Comment</i>
<i>CXCL11</i>	chr4:q21.1	rs7436646	0.36	
<i>CXCL12</i>	chr10:q11.21	rs2839695	0.080	
<i>CXCL9</i>	chr4:q21.1	rs3733236	0.060	
<i>IFNA1</i>	chr9:p21.3	rs1332190	0.67	
<i>IFNA2</i>	chr9:p21.3	rs615544	0.18	
<i>IFNA4</i>	chr9:p21.3	rs2383183	0.025	
<i>IFNA5</i>	chr9:p21.3	rs7021906	0.14	
<i>IFNA6</i>	chr9:p21.3	rs614541	0.23	
<i>IFNA7</i>	chr9:p21.3	rs28368137	0.34	
<i>IFNA8</i>	chr9:p21.3	rs1330322	0.067	
<i>IFNA10</i>	chr9:p21.3	rs12555631	0.32	
<i>IFNA13</i>	chr9:p21.3	rs643070	0.045	
<i>IFNA14</i>	chr9:p21.3	rs28368137	0.34	
<i>IFNA16</i>	chr9:p21.3	rs10964912	0.97	
<i>IFNA17</i>	chr9:p21.3	rs10964920	0.14	
<i>IFNA21</i>	chr9:p21.3	rs7047299	0.042	
<i>IFNB1</i>	chr9:p21.3	rs1051922	0.29	
<i>IFNE1</i>	chr9:p21.3	rs1556461	0.083	
<i>IFNK</i>	chr9:p21.2	rs4879540	0.26	
<i>IFNW1</i>	chr9:p21.3	rs10757189	0.036	
<i>IL28A</i>	chr19:q13.2	NA	NA	Failed genotyping QC
<i>IL28B</i>	chr19:q13.2	NA	NA	Failed genotyping QC
<i>IL29</i>	chr19:q13.2	rs7247086	0.12	

**D Genes involved in response to type I and III IFN (mediation and regulation)**

<i>Gene</i>	<i>Location</i>	<i>SNP with lowest P</i>	<i>P<sub>Chi2</sub></i>	<i>Comment</i>
<i>IFNAR1</i>	chr21:q22.11	rs17875880	0.18	
<i>IFNAR2</i>	chr21:q22.11	rs16990416	0.12	
<i>IL10RB</i>	chr21:q22.11	NA	NA	Failed assay design
<i>IL28RA</i>	chr1:p36.11	rs3932667	0.46	
<i>IRF9/ISGF3G</i>	chr14:q11.2	rs2236350	0.16	
<i>JAK1</i>	chr1:p31.3	rs4916004	0.039	
<i>PIAS1</i>	chr15:q23	rs8025474	0.042	
<i>PIAS2</i>	chr18:q21.1	rs3786258	0.38	
<i>PIAS3</i>	chr1:q21.1	rs17352344	0.22	
<i>PIAS4</i>	chr19:p13.3	rs2289863	0.00069	
<i>SOCS1</i>	chr16:p13.13	rs193779	0.24	
<i>SOCS3</i>	chr17:q25.3	rs8064821	0.88	
<i>STAT1</i>	chr2:q32.2	rs10199181	0.0016	
<i>STAT2</i>	chr12:q13.3	rs2066807	0.75	
<i>STAT3</i>	chr17:q21.2	rs17880368	0.019	
<i>STAT5A</i>	chr17:q21.2	rs8068688	0.74	
<i>STAT5B</i>	chr17:q21.2	rs6503691	0.013	

**E Genes regulated by type I IFN**

<i>Gene</i>	<i>Location</i>	<i>SNP with lowest P</i>	<i>P<sub>Chi2</sub></i>	<i>Comment</i>
<i>CXCL10</i>	chr4:q21.1	rs3921	0.35	
<i>TNFSF11</i>	chr13:q14	rs9594782	0.076	
<i>TNFSF13B</i>	chr13:q32-q34	rs9520835	0.032	
<i>TNFSF13</i>	chr17:p13.1	rs12942687	0.52	
<i>TNFRSF13B</i>	chr17:p11.2	rs4985700	0.094	
<i>TNFRSF17</i>	chr16:p13.1	rs11570158	0.27	
<i>TNFRSF13C</i>	chr22:q13.1-q13.31	rs7290134	0.43	

**F Other genes**

<i>Gene</i>	<i>Location</i>	<i>SNP with lowest P</i>	<i>P<sub>Chi2</sub></i>	<i>Comment</i>
<i>DQX1</i>	chr2:p13.1	rs6709863	0.035	
<i>RALBP1</i>	chr18:p11.22	rs17508182	0.076	

**G Genes that had published association to SLE**

<i>Gene</i>	<i>Location</i>	<i>SNP with lowest P</i>	<i>P<sub>Chi2</sub></i>	<i>Comment</i>
<i>ACE</i>	chr17:q23.3	rs4267385	0.15	
<i>C6orf125</i>	chr6:p21.31	rs594223	0.050	
<i>CCL2</i>	chr17:q12	rs3760396	0.33	
<i>CRP</i>	chr1:q23.2	rs1800947	0.33	
<i>CTLA4</i>	chr2:q33.2	rs231779	0.21	
<i>DNASE1</i>	chr16:p13.3	rs1053874	0.90	
<i>FCRL3</i>	chr1:q23.1	rs7528684	0.19	
<i>IL1A</i>	chr2:q13	rs1800587	0.89	
<i>IL1RN</i>	chr2:q13	rs380092	0.18	
<i>IL6</i>	chr7:p15.3	rs1474348	0.036	
<i>IL8</i>	chr4:q13.3	rs4694178	0.0048	
<i>ITPR3</i>	chr6:p21.31	rs2296329	0.039	
<i>MBL2</i>	chr10:q21.1	rs10824793	0.26	
<i>PADI4</i>	chr1:p36.13	rs2240340	0.96	

<sup>1</sup> 482 Swedish SLE cases and 536 controls.

**Table S4** The most promising SNPs in the eight genes identified in the discovery phase<sup>1</sup> (SNPs with  $P < 0.05$ ). The rs-number of the SNP with the lowest p-value in each gene is indicated in bold. Independence of association signals within the same gene was investigated with a conditional analysis accounting for the most strongly associated SNP in each gene.

<i>Gene</i>	<i>Chr</i>	<i>SNP</i>	<i>Position</i>	$P_{logistic}$	$P_{conditional}$	$r^2$	<i>Confirmatory phase</i>
<i>IKBKE</i>	1	<b>rs1539243</b>	203036182	0.0036	NA	1	Genotyped
<i>IKBKE</i>	1	rs17433930	203041134	0.011	0.28	0.33	Genotyped
<i>TANK</i>	2	rs3820998	161820633	0.0089	NA	0.99	
<i>TANK</i>	2	<b>rs3754974</b>	161838462	0.0062	NA	1	Genotyped
<i>TANK</i>	2	rs13397244	161839598	0.0067	NA	0.99	Genotyped
<i>TANK</i>	2	rs1267076	161848164	0.028	0.056	0.01	
<i>TANK</i>	2	rs12476789	161852196	0.0089	NA	0.99	Genotyped
<i>TANK</i>	2	rs1267078	161857178	0.036	0.063	0.01	
<i>TANK</i>	2	rs1267080	161864079	0.039	0.069	0.01	
<i>TANK</i>	2	rs16845704	161875201	0.038	1.00	0.94	
<i>TANK</i>	2	rs7600342	161880718	0.015	NA	0.99	Genotyped
<i>TANK</i>	2	rs3754972	161882525	0.0089	NA	0.99	Genotyped
<i>TANK</i>	2	rs3769975	161883914	0.024	0.81	0.87	
<i>TANK</i>	2	rs1267075	161885324	0.029	0.052	0.01	Genotyped
<i>TANK</i>	2	rs3769973	161889981	0.0081	NA	0.99	
<i>TANK</i>	2	rs3769972	161893004	0.011	NA	1	Genotyped
<i>TANK</i>	2	rs10178063	161899325	0.0089	NA	0.99	Genotyped
<i>TANK</i>	2	rs12471074	161914481	0.024	0.64	0.86	
<i>TANK</i>	2	rs3754971	161917272	0.024	0.81	0.87	
<i>STAT1</i>	2	rs1547550	191671231	0.015	0.41	0.29	
<i>STAT1</i>	2	rs2280232	191676272	0.044	0.029	0.01	
<i>STAT1</i>	2	rs7562024	191681027	0.048	0.97	0.37	
<i>STAT1</i>	2	rs16833155	191686883	0.0097	0.049	0.05	Failed genotyping
<i>STAT1</i>	2	rs10173099	191692838	0.0071	0.90	0.71	
<i>STAT1</i>	2	rs2030171	191694669	0.0036	0.51	0.71	Genotyped
<i>STAT1</i>	2	<b>rs10199181</b>	191699059	0.0013	NA	1	Failed genotyping
<i>STAT1</i>	2	rs16833172	191701575	0.0067	0.022	0.02	Genotyped
<i>STAT1</i>	2	rs17817900	191705373	0.011	0.037	0.02	Failed genotyping
<i>STAT1</i>	2	rs1467199	191706008	0.028	0.87	0.43	
<i>IL8</i>	4	<b>rs4694178</b>	74977723		NA	1	Genotyped
<i>NRP1</i>	10	rs2474726	33523567	0.039	0.44	0.20	
<i>NRP1</i>	10	rs734187	33524702	0.046	0.47	0.20	Genotyped
<i>NRP1</i>	10	rs2269103	33539226	0.012	0.31	0.90	Genotyped
<i>NRP1</i>	10	rs3904032	33560274	0.015	0.36	0.91	
<i>NRP1</i>	10	<b>rs1331314</b>	33564687	0.0023	NA	1	Genotyped
<i>NRP1</i>	10	rs11009314	33570967	0.0074	0.52	0.95	
<i>NRP1</i>	10	rs2073320	33593263	0.037	0.020	0.00	Genotyped
<i>TRAF6</i>	11	<b>rs5030482</b>	36466602	0.0028	NA	1	Genotyped
<i>TRAF6</i>	11	rs5030472	36470362	0.036	0.67	0.61	Genotyped
<i>TRAF6</i>	11	rs2303439	36470866	0.018	0.42	0.82	Failed genotyping
<i>STAT5B</i>	17	<b>rs6503691</b>	37647616	0.0100	NA	1	Genotyped
<i>PIAS4</i>	19	<b>rs2289863</b>	3979783	0.00099	NA	1	Genotyped

$P_{logistic}$  is the p-value for a logistic regression analysis under an additive model.

$P_{conditional}$  is the p-value in a additive logistic regression analysis conditioning on the best SNP in the gene.

$r^2$  is the pair-wise LD with the SNP with the lowest p-value in the gene.

<sup>1</sup> 482 Swedish SLE cases and 536 controls.



**Table S5** Results of the combined analysis for the Swedish discovery and confirmation SLE cohorts<sup>1</sup>

<i>Gene</i>	<i>CHR</i>	<i>SNP</i>	<i>bp</i>	<i>Minor/major alleles</i>	<i>MAF cases</i>	<i>MAF controls</i>	<i>P<sub>SNPtest</sub></i>	<i>Risk allele</i>	<i>OR (95% CI)</i>	<i>P<sub>logistic</sub></i>	<i>P<sub>conditional</sub></i>
<i>IKBKE</i>	1	rs1539243	204714410	T/C	0.16	0.18	<b>0.031</b>	C	1.19 (1.02-1.39)	0.029	0.51
<i>IKBKE</i>	1	rs17433930	204719362	G/A	0.07	0.09	<b>0.013</b>	A	1.33 (1.06-1.67)	0.011	NA
<i>TANK</i>	2	rs3754974	161721201	G/A	0.05	0.04	<b>0.0087</b>	G	1.44 (1.09-1.89)	0.0080	NA
<i>TANK</i>	2	rs13397244	161722337	G/A	0.05	0.04	<b>0.010</b>	G	1.42 (1.08-1.86)	0.0092	NA
<i>TANK</i>	2	rs12476789	161734935	G/A	0.05	0.04	<b>0.019</b>	G	1.38 (1.05-1.81)	0.017	NA
<i>TANK</i>	2	rs7600342	161763457	G/A	0.05	0.04	<b>0.049</b>	G	1.39 (1.06-1.82)	0.016	NA
<i>TANK</i>	2	rs3754972	161765264	A/T	0.05	0.04	<b>0.010</b>	A	1.42 (1.08-1.86)	0.0094	NA
<i>TANK</i>	2	rs1267075	161768063	G/A	0.19	0.18	0.75	G	1.02 (0.88-1.19)	0.77	0.61
<i>TANK</i>	2	rs3769972	161775743	G/A	0.05	0.04	<b>0.018</b>	G	1.38 (1.05-1.81)	0.017	NA
<i>TANK</i>	2	rs10178063	161782064	G/A	0.05	0.04	<b>0.0078</b>	G	1.44 (1.10-1.89)	0.0072	NA
<i>STAT1</i>	2	rs2030171	191577408	A/G	0.35	0.29	<b>1.2E-05</b>	A	1.31 (1.16-1.49)	1.0E-05	NA
<i>STAT1</i>	2	rs16833172	191584314	A/G	0.04	0.03	<b>0.015</b>	A	1.51 (1.09-2.09)	0.012	0.16
<i>IL8</i>	4	rs4694178	74831552	C/A	0.52	0.46	<b>5.2E-05</b>	C	1.26 (1.12-1.42)	6.1E-05	-
<i>NRP1</i>	10	rs734187	33524702	A/G	0.24	0.24	0.67	A	1.03 (0.90-1.18)	0.65	-
<i>NRP1</i>	10	rs2269103	33539226	T/G	0.11	0.11	0.31	T	1.10 (0.92-1.33)	0.34	-
<i>NRP1</i>	10	rs1331314	33564687	G/C	0.11	0.10	0.32	G	1.11 (0.92-1.34)	0.30	-
<i>NRP1</i>	10	rs2073320	33593263	A/G	0.38	0.37	0.42	A	1.05 (0.93-1.18)	0.43	-
<i>TRAF6</i>	11	rs5030482	36466602	C/T	0.12	0.14	<b>0.0094</b>	T	1.25 (1.05-1.49)	0.012	NA
<i>TRAF6</i>	11	rs5030472	36470362	T/C	0.09	0.12	<b>0.013</b>	C	1.28 (1.05-1.55)	0.012	0.50
<i>STAT5B</i>	17	rs6503691	37647616	T/C	0.09	0.10	0.44	C	1.08 (0.88-1.32)	0.38	-
<i>PIAS4</i>	19	rs2289863	3979783	C/T	0.27	0.29	0.19	T	1.09 (0.96-1.25)	0.18	-

<sup>1</sup>826 Swedish cases and 1 835 controls genotyped in the discovery and replication phases including controls genotyped on the 1M chip

Genotypes for rs17433930, rs3754974, rs13397244, rs12476789, rs7600342, rs3754972, rs10178063, rs2030171, rs16833172, rs4694178, rs734187, rs1331314 and rs5030482 were imputed in the Swedish control genotyped on the 1M chip

MAF= Minor Allele Frequency, NA= Not Available, CI= Confidence Interval

P<sub>conditional</sub> on the SNP with lowest P-value in each gene: IKBKE-rs17433930, TANK-rs10178063, STAT1-rs2030171 and TRAF6-rs5030482.

**Table S6** Complete results of the meta-analysis of the Swedish and US cohorts

Gene	SNP	Alleles	Combined Swedish dataset <sup>1</sup>					US dataset <sup>2</sup>					Meta-analysis <sup>5</sup>				
			Risk allele	MAF cases	MAF controls	P <sup>3</sup>	OR (95% CI)	Risk allele	MAF cases	MAF controls	P <sup>3</sup>	OR (95% CI) <sup>4</sup>	Risk allele	P	Corrected P <sup>6</sup>	OR (95% CI) <sup>4</sup>	Heterogeneity <sup>7</sup>
<i>IKBKE</i>	rs1539243	T/C	C	0.16	0.18	<b>0.031</b>	1.19 (1.02-1.39)	C	0.14	0.17	<b>0.0028</b>	1.20 (1.07-1.35)	C	<b>2.6E-04</b>	<b>0.0054</b>	1.19 (1.09-1.31)	0.95
<i>IKBKE</i>	rs17433930	G/A	A	0.07	0.09	<b>0.013</b>	1.33 (1.06-1.67)	A	0.06	0.07	<b>0.0021</b>	1.33 (1.11-1.58)	A	<b>1.0E-04</b>	<b>0.0022</b>	1.33 (1.16-1.53)	0.99
<i>TANK</i>	rs3754974	G/A	G	0.05	0.04	<b>0.0087</b>	1.44 (1.09-1.89)	NA	0.04	0.04	0.98	0.99 (0.80-1.22)	NA	0.22	1.0	1.13 (0.96-1.34)	0.033
<i>TANK</i>	rs13397244	G/A	G	0.05	0.04	<b>0.010</b>	1.42 (1.08-1.86)	NA	0.04	0.04	0.98	0.99 (0.80-1.22)	NA	0.23	1.0	1.13 (0.96-1.33)	0.038
<i>TANK</i>	rs12476789	G/A	G	0.05	0.04	<b>0.019</b>	1.38 (1.05-1.81)	NA	0.04	0.04	0.96	0.99 (0.80-1.23)	NA	0.29	1.0	1.12 (0.95-1.32)	0.063
<i>TANK</i>	rs7600342	G/A	G	0.05	0.04	<b>0.049</b>	1.39 (1.06-1.82)	NA	0.04	0.04	0.87	0.95 (0.76-1.19)	NA	0.43	1.0	1.09 (0.92-1.29)	0.037
<i>TANK</i>	rs3754972	A/T	A	0.05	0.04	<b>0.010</b>	1.42 (1.08-1.86)	NA	0.04	0.04	0.95	0.96 (0.77-1.20)	NA	0.24	1.0	1.12 (0.94-1.32)	0.028
<i>TANK</i>	rs1267075	G/A	G	0.19	0.18	0.75	1.02 (0.88-1.19)	NA	0.17	0.17	0.87	0.99 (0.89-1.11)	NA	0.99	1.0	1.00 (0.92-1.10)	0.71
<i>TANK</i>	rs3769972	G/A	G	0.05	0.04	<b>0.018</b>	1.38 (1.05-1.81)	NA	0.04	0.04	0.95	0.96 (0.77-1.20)	NA	0.29	1.0	1.10 (0.93-1.30)	0.043
<i>TANK</i>	rs10178063	G/A	G	0.05	0.04	<b>0.0078</b>	1.44 (1.10-1.89)	NA	0.04	0.04	0.93	0.95 (0.77-1.19)	NA	0.23	1.0	1.11 (0.94-1.32)	0.019
<i>STAT1</i>	rs2030171	A/G	A	0.35	0.29	<b>1.2E-05</b>	1.31 (1.16-1.49)	A	0.37	0.34	<b>0.018</b>	1.11 (1.02-1.21)	A	<b>3.3E-05</b>	<b>6.9E-04</b>	1.17 (1.09-1.26)	0.029
<i>STAT1</i>	rs16833172	A/G	A	0.04	0.03	<b>0.015</b>	1.51 (1.09-2.09)	A	0.03	0.02	0.16	1.23 (0.95-1.59)	A	<b>0.016</b>	0.34	1.33 (1.09-1.63)	0.34
<i>IL8</i>	rs4694178	C/A	C	0.52	0.46	<b>5.2E-05</b>	1.26 (1.12-1.42)	C	0.43	0.41	0.064	1.13 (1.04-1.23)	C	<b>4.0E-04</b>	<b>0.0084</b>	1.17 (1.10-1.26)	0.12
<i>NRP1</i>	rs734187	A/G	A	0.24	0.24	0.67	1.03 (0.90-1.18)	NA	0.25	0.25	0.66	1.01 (0.92-1.12)	A	0.56	1.0	1.02 (0.94-1.10)	0.80
<i>NRP1</i>	rs2269103	T/G	T	0.11	0.11	0.31	1.10 (0.92-1.33)	T	0.11	0.10	0.065	1.11 (0.97-1.28)	T	<b>0.036</b>	0.75	1.11 (1.00-1.24)	0.96
<i>NRP1</i>	rs1331314	G/C	G	0.11	0.10	0.32	1.11 (0.92-1.34)	G	0.12	0.11	0.11	1.11 (0.97-1.26)	G	0.061	1.0	1.11 (1.00-1.23)	0.99
<i>NRP1</i>	rs2073320	A/G	A	0.38	0.37	0.42	1.05 (0.93-1.18)	NA	0.38	0.39	0.61	0.98 (0.90-1.06)	NA	0.94	1.0	1.00 (0.94-1.07)	0.35
<i>TRAF6</i>	rs5030482	C/T	T	0.12	0.14	<b>0.0094</b>	1.25 (1.05-1.49)	T	0.13	0.14	0.12	1.10 (0.97-1.24)	T	<b>0.0097</b>	0.20	1.14 (1.03-1.26)	0.22
<i>TRAF6</i>	rs5030472	T/C	C	0.09	0.12	<b>0.013</b>	1.28 (1.05-1.55)	C	0.11	0.11	0.19	1.09 (0.96-1.25)	C	<b>0.020</b>	0.42	1.15 (1.03-1.28)	0.20
<i>STAT5B</i>	rs6503691	T/C	C	0.09	0.10	0.44	1.08 (0.88-1.32)	NA	0.11	0.11	0.78	0.98 (0.86-1.12)	NA	0.91	1.0	1.01 (0.90-1.13)	0.44
<i>PIAS4</i>	rs2289863	C/T	T	0.27	0.29	0.19	1.09 (0.96-1.25)	NA	0.26	0.26	0.72	0.98 (0.89-1.08)	NA	0.76	1.0	1.02 (0.95-1.10)	0.19

<sup>1</sup>826 Swedish cases and 1 835 controls genotyped in the discovery and replication phases including controls genotyped on the 1M chip, P-values calculated using SNPtest

<sup>2</sup>1 310 US SLE cases and 7 859 controls genotyped in a GWAS. Genotypes for rs17433930, rs3754974, rs13397244, rs12476789, rs7600342, rs3754972, rs3769972, rs10178063, rs2030171, rs16833172, rs4694178, rs734187, rs2269103, rs1331314 and rs5030482 were imputed in this dataset as described in Gateva *et al.* P-values calculated using SNPtest

<sup>3</sup>P-value calculated using SNPtest

<sup>4</sup>Odds ratios are calculated relative to the risk allele defined in the analysis of the combined Swedish cohort

<sup>5</sup>Meta-analysis including 2 136 SLE cases and 9 694 controls

<sup>6</sup>P-value corrected for the 21 tested SNPs

<sup>7</sup>P-value test for heterogeneity of odds ratios

MAF= Minor Allele Frequency, NA= Not Available, CI= Confidence Interval